| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y |
| 06 Oct 2026 |
8-K: Results of Operations and Financial Condition
In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid), which was completed on August 31, 2026, BioMarin Pharmaceutical In... |
| 30 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of factors, including the... |
| 14 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 10, 2026, the Board of Directors (the Board) of BioMarin Pharmaceutical Inc. (the Company) increased the size of the Board from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., to the Board, to be effective Se... |
| 01 Sep 2026 |
8-K: Other Events
As previously reported in the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (“SEC”) on August 18, 2026, BioMarin Pharmaceutical Inc., a Delaware corporation (“BioMarin”), entered into a Share Purchase ... |
| 31 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea |
| 18 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
***Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential. Such omitted information is indicated by brackets (“[***]”)... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million |
| 04 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On June 2, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the Company) held its 2026 Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, BioMarin’s stockholders approved an amendment to the BioMarin Pharmaceutica... |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
First Quarter 2026 Total Revenues Increased Year-over-year to $766 million |
| 27 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
the LENDERS and ISSUING BANKS from time to time party hereto |
| 23 Apr 2026 |
8-K: Other Events
As previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. (“BioMarin”) and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin (“Merger Sub”) entered into an Agreement and Plan of Merger (the “Merger Agreemen... |
| 16 Mar 2026 |
8-K: Other Events
On March 16, 2026, BioMarin Pharmaceutical Inc. (“BioMarin”) announced its decision to discontinue dosing and enrollment in its Phase 2 trials for VOXZOGO in Turner Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency following the o... |
| 23 Feb 2026 |
8-K: Results of Operations and Financial Condition
Full-year 2025 Total Revenues Increased 13% Y/Y to $3.2 Billion, Led by 9% Revenue Growth for Enzyme Therapies and 26% Revenue Growth for VOXZOGO® |
| 12 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE, dated as of February 12, 2026, by and among the Issuer (as defined below), the Guarantors (as defined below) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), registrar and paying agent. |
| 29 Jan 2026 |
8-K: Regulation FD Disclosure
SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (“BioMarin”) announced today that it priced its previously announced offering of $850 million of 5.500% senior unsecured notes due 2034 (the “No... |
| 26 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
On December 19, 2025, BioMarin entered into the Merger Agreement with Amicus and Merger Sub, providing for the Merger, with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin. The Acquisition is expected to close in the... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Exhibit 99.1 44th Annual J.P. Morgan Healthcare Conference Alexander Hardy Greg Friberg Chief Executive Officer Chief R&D Officer BioMarin Pharmaceutical Inc. January 12, 2026 |
| 22 Dec 2025 |
8-K: Other Events
On December 19, 2025, BioMarin Pharmaceutical Inc. announced its decision to discontinue development of BMN 349, an oral therapeutic for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease. |
Loading...